New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2013
10:11 EDTSWC, RWT, NFLX, PLOW, ALTR, ABBV, RKT, VECO, SWY, PRI, MHR, CPA, ATI, MLNX, APD, TIF, RGA, PKY, ENR, AAPL, ALB, AIG, FLSOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Albermarle (ALB) downgraded to Hold from Buy at Deutsche Bank... Allegheny Technologies (ATI) downgraded to Neutral from Buy at Goldman... Altera (ALTR) downgraded to Market Perform from Outperform at William Blair... Apple (AAPL) downgraded to Hold from Buy at Jefferies... Coach (COH) downgraded to Neutral from Buy at ISI Group... Copa Holdings (CPA) downgraded to Neutral from Buy at Goldman... Douglas Dynamics (PLOW) downgraded to Neutral from Outperform at Credit Suisse... Energizer (ENR) downgraded to Market Perform from Outperform at BMO Capital... Magnum Hunter (MHR) downgraded to Hold from Buy at Jefferies... Netflix (NFLX) downgraded to Neutral from Outperform at Credit Suisse... Parkway Properties (PKY) downgraded to Sell from Hold at Cantor... Primerica (PRI) downgraded to Reduce from Neutral at SunTrust... Redwood Trust (RWT) downgraded to Market Perform from Outperform at JMP Securities... Reinsurance Group (RGA) downgraded to Equal Weight from Overweight at Morgan Stanley... Safeway (SWY) downgraded to Underweight from Equal Weight at Barclays... Stillwater Mining (SWC) downgraded to Neutral from Outperform at Credit Suisse... Tiffany (TIF) downgraded to Hold from Buy at Canaccord... Veeco (VECO) downgraded to Neutral from Buy at UBS... Flowserve (FLS) downgraded to Neutral from Outperform at Wedbush... Air Products (APD) downgraded to Neutral from Positive at Susquehanna... Rock-Tenn (RKT) downgraded to Underperform from Outperform at CLSA... IAMGOLD (IAG) downgraded to Hold from Buy at Stifel Nicolaus... Mellanox (MLNX) downgraded to Hold from Buy at Craig-Hallum... AbbVie (ABBV) downgraded to Neutral from Long-Term Buy at Hilliard Lyons.
News For ALB;ATI;ALTR;AAPL;CPA;PLOW;ENR;MHR;NFLX;PKY;PRI;RWT;RGA;SWY;SWC;TIF;VECO;FLS;APD;RKT;AIG;MLNX;ABBV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 >>
January 29, 2016
16:00 EDTNFLX, AAPLOptions Update; January 29, 2016
Subscribe for More Information
10:36 EDTAAPLActive puts @ CBOE: IWM VMW NEM SPY XRT AAPL
Subscribe for More Information
10:27 EDTAAPLActive calls: IWM F DXJ ABT FXI AAPL EEM COP
Subscribe for More Information
10:15 EDTAAPLApple may look into developing original shows for i Tunes, The Street reports
Apple is talking to TV producers and Hollywood studios about investing and developing original TV shows, reports The Street. According to two people with knowledge of the overtures, Apple has begun sounding out studios although it has yet to sign any agreements. One deal would have Apple announcing exclusive content as part of a cable-like offering in September. Reference Link
09:52 EDTABBVAbbVie: 2% of FY15 operational growth from price increases
Subscribe for More Information
09:44 EDTABBVGilead slips as another drug enters Hepatitis C virus space
Shares of Gilead (GILD), a leader in the hepatitis C virus treatment space, are sliding this morning after one competitor's hep C drug was granted FDA approval and another's sales disappointed. Additionally, Gilead reported its own news, announcing a shakeup of the roles held by its top executives. MERCK APPROVAL: Merck (MRK) announced last night that the FDA has approved Zepatier for the treatment of adult patients with chronic hepatitis C virus, or HCV, genotype, or GT, 1 or GT4 infection. Merck has established a list price of $54,600 for a 12-week regimen of Zepatier, which the company said it believes to "be in the range of net prices for other commonly used HCV direct-acting antiviral regimens at 12 weeks of therapy." In contrast, a 12-week regimen of Gilead's Sovaldi is reported to be priced at $84,000. Merck added that it anticipates that this price, as well as its "strategy to seek broad coverage across commercial and public segments," will help broaden and accelerate patient access to treatment. ABBVIE RESULTS: Meanwhile, Gilead competitor AbbVie (ABBV) announced financial results for the fourth quarter this morning. AbbVie announced Q4 sales of Viekira Pak, its own hep C treatment, of $554M, including U.S. sales of $197M and international sales of $357M. Analysts expected AbbVie to report Q4 Viekira sales of $568.5M, according to a Bloomberg consensus estimate that factored in four forecasts. EXECUTIVE CHANGES: Additionally, Gilead announced this morning that current chairman and CEO John Martin will assume the role of executive chairman, effective March 10. John Milligan, currently president and COO, will be promoted to CEO and appointed to the company's board. PRICE ACTION: In morning trading, Gilead shares slipped 3.5% to $84.50, while AbbVie fell 2.4% to $54.53 and Merck (MRK) gained 1% to $49.75.
09:38 EDTABBVAbbVie sees FY16 Humira revenue growth in high-teens
Subscribe for More Information
09:35 EDTABBVAbbVie sees Q1 adjusted EPS $1.13-$1.15, consensus $1.15
Guidance excludes 11c of non-cash amortization and specified items. Sees Q1 revenue growth just above 20%, consensus $6.06B.
09:34 EDTAAPLActive equity options trading on open: AMZN MSFT FB AAPL GILD GE
Subscribe for More Information
09:30 EDTABBVAbbVie says FY16 to be 'milestone-filled'
Subscribe for More Information
09:21 EDTABBVOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Gigamon (GIMO), up 17.7%... Fortinet (FTNT), up 10%... Flextronics (FLEX), up 10%... Skyworks (SWKS), up 5.7%... Seagate Technology (STX), up 4.9%.. Microsoft (MSFT), up 4.6%. ALSO HIGHER: Inovio Pharmaceuticals (INO), up 8.1% after CEO says Zika vaccine could enter human testing this year... J.C. Penney (JCP), up 2.1% after being upgraded to Neutral from Underperform at Credit Suisse... BRF S.A. (BRFS), up 3.1% after being upgraded to Buy from Hold at Deutsche Bank... Axiall (AXLL), up 83.4% after rejecting $20 per share acquisition proposal from Westlake Chemical (WLK)... Energous (WATT), up 12% after Bloomberg reported that Apple (AAPL) is working with partners in the U.S. and Asia to develop new wireless charging technology. DOWN AFTER EARNINGS: Amazon.com (AMZN), down 10.1%... Electronic Arts (EA), down 6.2%... AbbVie (ABBV), down 4%... American Airlines (AAL), down 1.3%. ALSO LOWER: Gilead Sciences (GILD), down 5.5% after CEO John Martin to assume role of executive chairman and COO John Milligan will be promoted to CEO.
08:28 EDTAAPLEnergous rises after Apple said to be at work on wireless charging
A Bloomberg report that said Apple (AAPL) is working with partners in the U.S. and Asia to develop new wireless charging technology did not mention Energous (WATT), which is a development-stage company exploring technology that can enable wire-free charging for electronic devices. In pre-market trading, Energous shares rose 10% to $5.25.
07:54 EDTABBVAbbVie backs FY16 adjusted EPS $4.90-$5.10, consensus $5.03
Subscribe for More Information
07:54 EDTABBVAbbVie reports Q4 adjusted net revenue $6.36B, consensus $6.39B
Global HUMIRA sales increased 16% on an operational basis to $3.72B, excluding the impact of foreign exchange. Exceptional U.S. HUMIRA growth of 20.7% was driven by continued momentum across all three major market categories - rheumatology, dermatology and gastroenterology. International HUMIRA sales growth was also strong in the fourth quarter, up 9.7 percent on an operational basis. Reported international HUMIRA sales growth in the quarter was reduced by 13.1 percent due to unfavorable foreign exchange. Fourth-quarter global IMBRUVICA net revenue was $343 million, with U.S. sales of $295 million and international profit sharing of $48 million for the quarter.
07:52 EDTABBVAbbVie reports Q4 adjusted EPS $1.13, consensus $1.12
Reports Q4 revenue $6.40B, consensus $6.39B.
07:49 EDTABBVBristol-Myers, AbbVie receive 'positive' CHMP opinion for Empliciti
Subscribe for More Information
06:28 EDTAAPLApple working on wireless-charged phone, Bloomberg says
Apple is working with partners in the U.S. and Asia to create new wireless charging technology that could work on mobile devices possibly as soon as next year, Bloomberg reports, citing people familiar with the plans. Apple is eyeing new technologies that would allow iPhones and ipads to be powered from further away than charging mats, the report says. Reference Link
06:03 EDTAPDAir Products sees FY16 EPS $7.25-$7.50, consensus $7.36
Subscribe for More Information
06:02 EDTAPDAir Products sees Q2 EPS $1.78-$1.83, consensus $1.75
Subscribe for More Information
06:02 EDTAPDAir Products reports Q1 EPS $1.78, consensus $1.71
Reports Q1 revenue $2.36B, consensus $2.44B.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use